🚨 New study: Evolocumab shows strong CV benefits in older adults (≥75 yrs) with ASCVD! 📉 Lower LDL-C, reduced events (HR: 0.79, NNT: 19), & no major safety concerns. Time to rethink lipid guidelines for seniors? 🔬💙 #Cardiology #LipidLowering #Evolocumab
